Crescent Biopharma (GYRE) Financial Statements & Analysis

Crescent Biopharma (GYRE) Income Statement

Crescent Biopharma reported revenue of $116.59M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 10.2% from $105.76M a year earlier. Net income was $5.03M, down 58.4% year over year, a net margin of 4.3%. Gross margin was 95.4% and operating margin 9.9%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $29.11M, down 2.1% from the same quarter a year earlier.

Crescent Biopharma Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Crescent Biopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	116.59	105.76	113.45	102.29	7.34	7.34	20.95	0.00	0.01	1.02
Cost of Revenue	5.42	3.88	4.64	4.79	7.67	7.38	9.16	0.15	0.15	0.17
Gross Profit	111.17	101.87	108.81	97.50	-0.33	-0.04	11.79	-0.15	-0.14	0.85
Operating Expenses
Research & Development	13.70	12.02	13.78	16.69	64.57	68.89	52.98	43.86	21.47	12.85
Selling, General & Administrative	85.98	73.62	75.82	71.61	18.82	18.96	16.18	13.27	12.35	9.99
Operating Expenses	99.68	85.64	176.04	88.29	83.39	87.85	69.16	57.13	33.83	22.67
Operating Income	11.49	16.23	-67.23	9.20	-83.73	-87.89	-57.37	-57.28	-33.82	-21.82
Other Income/Expense
Interest Income	1.75	1.55	1.04	1.58	0.04	0.38	0.56	2.15	3.77	0.26
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.12	0.00	0.00	0.00	0.00
Other Income/Expense	2.95	5.44	-9.74	0.21	-4.21	-0.04	1.13	2.10	3.77	0.26
Income
Income Before Tax	14.44	23.22	-76.97	9.41	-87.93	-87.93	-56.24	-55.18	-30.06	-21.56
Income Tax Expense	4.56	5.32	8.52	5.10	0.00	6.17	-0.70	0.00	0.00	0.00
Net Income	5.03	12.09	-92.93	2.30	-87.93	-87.93	-55.54	-55.18	-30.06	-21.56
Net Income - Continuous Operations	5.03	17.90	-92.93	2.30	-87.93	23.44	-55.54	-55.18	-30.06	-21.56
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	16.96	17.82	20.33	10.33	-87.64	-87.60	-56.10	-55.03	-33.82	-21.65
EBIT	11.49	16.23	19.21	9.20	-	-87.89	-	-	-	-
Depreciation & Amortization	2.52	1.59	1.11	1.13	0.29	1.93	0.14	0.15	0.15	0.17
Earnings Per Share
Basic EPS	-	-	-1.00	-	-3.00	-	-3.00	-4.00	-3.00	-7.00
Diluted EPS	-	-	-1.00	-	-3.00	-	-3.00	-4.00	-3.00	-7.00
Basic Shares Outstanding	89.34	85.09	65.83	63.59	30.64	61.32	19.18	12.00	11.21	3.42
Diluted Shares Outstanding	103.18	102.29	65.83	75.69	30.64	66.71	19.18	12.00	11.21	3.42

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Crescent Biopharma Financial Statements

What was Crescent Biopharma's revenue in fiscal 2025?

Crescent Biopharma reported revenue of $116.59M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 10.2% from $105.76M a year earlier.

Is Crescent Biopharma profitable?

Yes. Crescent Biopharma earned net income of $5.03M in fiscal 2025, a net margin of 4.3%. In fiscal 2024 it earned $12.09M.

What is Crescent Biopharma's operating margin?

Crescent Biopharma's operating income was $11.49M on revenue of $116.59M in fiscal 2025, an operating margin of 9.9%, compared with 15.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition